Xiaowei Wu is a Principal Investigator of Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Zhongshan Institute for Drug Discovery, the Institutes of Drug Discovery and Development, CAS. He obtained his PhD degree in 2017 from Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences (CAS), China. From 2017 to 2021, He worked as a post-doc at H. Lee Moffitt Cancer Center & Research Institute and Baylor College of Medicine, respectively. Dr. Wu’s primary interest is the development of novel small-molecule therapeutics for the treatment of cancer and other diseases.
Research Areas
Education
2008.9-2012.6 B.S. in Pharmacy, Sichuan University
2012.9-2017.6 Ph.D in Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of SciencesExperience
Work Experience
2017.8-2018.6 Postdoctoral fellow, Department of Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
2018.6-2021.02 Postdoctoral fellow, Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, Texas, USA
Publications
1. Xiaowei Wu, Bao Wang, Shengbin Zhou, Yu Zhou, Hong Liu. Ruthenium-Catalyzed Redox-Neutral [4+1] Annulation of Benzamides and Propargyl alcohols via C-H Bond Activation. ACS Catalysis, 2017, 7, 2494-2499.
2. Xiaowei Wu, Bao Wang, Yu Zhou, Hong Liu. Propargyl alcohols as one-carbon synthons: redox-neutral Rh (III)-catalyzed C-H bond activation for the synthesis of isoindolinones bearing a quaternary carbon. Organic Letters, 2017, 19, 1294-1297.
3. Xiaowei Wu, Haitao Ji. Ruthenium(II)-Catalyzed Regio- and Stereoselective C−H Allylation of Indoles with Allyl Alcohols. Organic Letters, 2018, 20, 2224-2227. Highlighted by Synfacts and ChemistryViews.
4. Xiaowei Wu, Yangbin Lu, Jin Qiao, Wenhao Dai, Xiuwen Jia, Hangcheng Ni, Xiaoning Zhang, Hong Liu, and Fei Zhao. Rhodium(III)-Catalyzed C–H Alkenylation/Directing Group Migration for the Regio- and Stereoselective Synthesis of Tetrasubstituted Alkenes. Organic Letters, 2020, 22, 9163-9168.
5. Xiaowei Wu, Dengyou Zhang, Shengbin Zhou, Feng Gao, Hong Liu. Site-specific indolation of proline-based peptides via copper(II)-catalyzed oxidative coupling of tertiary amine N-oxides. Chemical Communications, 2015, 51, 12571-12573.
6. Xiaowei Wu, Mengdi Dai, Jihui Zhao, Yulan Wang, Chunpu Li, Xia Peng, Rongrong Cui, Bao Wang, Yang Dai, Dan Feng, Hualiang Jiang, Meiyu Geng, Jing Ai, Mingyue Zheng, Hong Liu. Design, Synthesis and pharmacological evaluation of pyrazolo[3,4-d]pyridazinone derivatives as covalent FGFR inhibitors. Acta Pharmaceutica Sinica B. 2021, 11, 781-794.
7. Yulan Wang,# Yang Dai,# Xiaowei Wu (co-first author),# Fei Li, Bo Liu, Chunpu Li, Qiufeng Liu, Yuanyang Zhou, Bao Wang, Mingrui Zhu, Rongrong Cui, Xiaoqin Tan, Zhaoping Xiong, Jia Liu, Minjia Tan, Yechun Xu, Mei-Yu Geng, Hualiang Jiang, Hong Liu, Jing Ai, Mingyue Zheng. The Discovery and Development of a Series of Pyrazolo[3,4-d]pyridazinone Compounds as Novel Covalent FGFR Inhibitors by Rational Drug Design. J. Med. Chem. 2019, 62, 7473-7488.
Research Interests
Medicinal chemistry, the development of transition-metal-catalyzed reactions and their application in the medicinal chemistry